Biogen to Halt Work on Opicinumab, Steer Focus Toward Parkinson’s Disease
Biogen reported its Q3 2020 financial results today, highlighting that its total revenues had reached $3.3 million. However, this was a 6% decrease from the third quarter of 2019, and the company stated that it would be halting work on opicinumab, its experimental multiple sclerosis (MS) drug.